Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 4/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.44 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497340 | 0.98 | KEAP1 (0.54) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497321 | 0.96 | KEAP1 (0.51) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497348 | 0.95 | CALCRL (0.50) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497328 | 0.93 | KEAP1 (0.52) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497369 | 0.92 | KEAP1 (0.48) | KEAP1CALCRLPRMT5WDR77NMUR2 | |
| SCHEMBL31497341 | 0.92 | CALCRL (0.52) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497325 | 0.92 | CALCRL (0.52) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497333 | 0.91 | CALCRL (0.52) | KEAP1CALCRLPRMT5WDR77CAPN1 | |
| SCHEMBL31497326 | 0.89 | CALCRL (0.46) | KEAP1CALCRLPRMT5WDR77 | |
| SCHEMBL9082723 | 0.85 | CALCRL (0.55) | KEAP1CALCRLPRMT5WDR77CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388623-A1 | PEPTIDE INHIBITOR AND USE THEREOF | CHENGDU BRILLIANT INSPIRATION BIOTHERAPEUTICS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4545551-A1 | PEPTIDE INHIBITOR AND USE THEREOF | Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd (CN) | 2025-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388623-A1 | PEPTIDE INHIBITOR AND USE THEREOF | VIP, TGFB1, FN1 | KEAP1 3525/4885CALCRL 405/4885PRMT5 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.